Briacell Therapeutics -CW27BCTXWPreferred / convertible
13F holders, Q4 2025 (December 31)7holders +4
4new positions
1sold out
$0.04avg. 13F price*
At the end of Q4 2025, 7 institutions reported holding Briacell Therapeutics -CW27 (BCTXW) in their 13F filings, up 4 from Q3 2025. 4 opened new positions and 1 sold out. The largest holders were Susquehanna International Group, LLP ($4K), Redmond Asset Management, LLC ($2K) and HRT Financial LP ($1K).
- Company
- Briacell Therapeutics -CW27
- CUSIP
- 10778Y112
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $6K |
| Exits | 1 | $575 |
All 13F filers, Q3 2025 → Q4 2025: 114,473 shares bought and 18,264 shares sold, net +96,209 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Susquehanna International Group, LLP | — | New | 67,111 | $4K |
| Redmond Asset Management, LLC | — | No change | 75,000 | $2K |
| HRT Financial LP | — | New | 20,844 | $1K |
| Virtu Financial LLC | — | New | 26,293 | $1K |
| L1 Global Manager Pty Ltd | — | — | 7,000 | $370 |
| NFSG Corp | — | No change | 1,000 | $53 |
| Royal Bank of Canada | — | New | 225 | $0 |
"% of holder's portfolio" is BCTXW's weight in each manager's 13F, not the share of Briacell Therapeutics -CW27 the manager owns.